



WKN: 792183 ISIN: DE0007921835 Land: Deutschland

Nachricht vom 20.08.2020 | 07:00

Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous

20.08.2020 / 07:00

The issuer is solely responsible for the content of this announcement.

Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020

HALLE (SAALE) / MUNICH, Germany, 20 August 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Half Year Results for 2020 on Thursday, August 27, 2020. The company will host a conference call and webcast open to the public. The Half Year Results 2020 will be available to download on the company website (www.vivoryon.com/investors-news/financial-information/).

Conference call details

Date: Thursday, August 27, 2020

Time: 3:00 pm CEST / 09:00 am EDT

Access Code: 8118230#

From Germany: +49 (0)69 2222 2018

From UK: +44 (0)330 336 9411

From USA: +1 929 477 0448

Webcast details

A live webcast and accompanying slides will be made available at: www.vivoryon.com/investors-news/financial-information/

###

For more information, please contact:

Vivoryon Therapeutics AG

Dr. Ulrich Dauer, CEO

Email: contact@vivoryon.com

Trophic Communication

Gretchen Schweitzer, Joanne Tudorica

Tel.: +49 172 861 8540 / +49 176 2103 7191

Email: _vivoryon@trophic.eu

Notes to Editors:

About Vivoryon Therapeutics AG

With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QC and QPCTL inhibitors in oncology and other indications. In addition, the Company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.

www.vivoryon.com

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which such statement is based.

20.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de

Language:	English
Company:	Vivoryon Therapeutics AG Weinbergweg 22 06120 Halle/Saale Germany
Phone:	+49 (0)345 555 9900
Fax:	+49 (0)345 555 9901
E-mail:	contact@vivoryon.com
Internet:	www.vivoryon.com
ISIN:	DE0007921835
WKN:	792183
Listed:	Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID:	1120785

End of News

DGAP News Service

DGAP – ein Service der EQS Group AG

[Twitter](#) | [Impressum](#) | [AGB](#) | [Datenschutzhinweise](#) | [Cookie-Richtlinie](#)